Early-career surgeons can safely and efficiently transition to robotic pancreaticoduodenectomy, achieving proficiency by case 23.

• Mean operative time dropped from 524 to 309 minutes (p < 0.001).
• Clinically relevant pancreatic fistula rates fell from 31.8% to 5.4% (p = 0.012).

Emphasis on mentorship in high-volume settings is crucial for successful outcomes.

• Conversion to open surgery occurred in just 3.8% of cases, with no 90-day mortality.

Surgeons treating T1 ampullary cancer need to consider high upstaging rates and significant survival disparities based on pathologic classification.

• In this cohort of 244 T1 ampullary cancer patients, 75% underwent resection, but 68% were upstaged to higher T classifications post-surgery.
• Five-year overall survival rates were starkly different: 36% for clinical T1N0 vs. 75% for pathologic T1N0 patients.

Given these findings, pancreatoduodenectomy is recommended over local resection for better outcomes.

• Independent predictors for poor survival include pathologic N1 (HR: 2.12) and poorly differentiated tumors (HR: 4.05).

A recent study highlights the critical need to adjust how we identify and manage chyle leak after pancreatic surgery.

• Chyle leak occurred in 11% of patients; risk factors included a minimally invasive approach and maximum drainage volume.
• Patients with high drainage volume (≥300 ml/day) and triglyceride-rich but non-milky drainage faced longer hospital stays (19 days) compared to those with smaller volumes (14 days).

Surgeons should consider triglyceride-rich drainage as clinically relevant, regardless of appearance, for better patient management.

Surgeons trained in dedicated hepato-pancreato-biliary fellowships see better patient outcomes after HP cancer surgeries.

• Graduates of HPB fellowships achieved a 47.7% likelihood of textbook outcomes (TOS), compared to 45.2% for surgical oncology and 42.8% for transplant fellowship graduates.
• Patients operated by HPB fellowship graduates often had higher comorbidity scores and greater urgencies, highlighting the need for tailored surgical approaches.

Improving HP surgery training for general surgical oncology fellows could enhance overall outcomes.

• Early and mid-career HPB fellowship graduates notably outperform their peers in achieving TOS.

High-volume hospitals improve survival and reduce costs for necrotizing pancreatitis patients.

• Patients at high-volume centers had lower odds of mortality (odds ratio: 0.78) compared to low-volume hospitals.
• Even with higher overall mortality rates, high-volume hospitals had lower mortality for intervention-only patients (7.5% vs 12.0%, p < 0.001).
• High-volume centers also associated with shorter hospital stays and lower healthcare costs.

Consider directing patients to high-volume centers for better outcomes and resource management.

Patient-derived organoid testing shows promise for tailoring therapy in pancreatic ductal adenocarcinoma.

• 91% of organoids matched to standard-of-care regimens, with 34% of poorly matched cases potentially qualifying for more effective options.
• Patients receiving well-matched neoadjuvant chemotherapy showed significantly better CA 19-9 response (60% normalization) and lymph node down-staging (69% N0) compared to poorly matched cases (29% normalization, 33% N0).

Matching therapy to organoid profiles could enhance survival rates—median overall survival rose from 19.5 to 30.3 months.

An innovative algorithm from routine data can effectively classify 30-day postoperative complications in hepatobiliary surgery, helping surgeons better understand patient outcomes.

• Among 959 liver resections, the algorithm achieved an impressive macro-f1-score of 0.962 and a sensitivity of 0.950.
• Major complications were observed in 18% of cases, with a 2.6% mortality rate.

This tool outperforms machine learning approaches and allows for real-time complication surveillance and quality evaluation.

• Misclassification was low at 3.2%, primarily linked to ICU coding issues.